THE WIRE · № 74852
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
01 THE MACHINE READ
WHY IT MATTERS.
Sustained IBD efficacy data support existing franchises but the release contains no pricing, guidance, or market share detail.
Confirmatory IBD data, little new for valuation
Competitor readouts in same IBD class
Crowded IBD market limits incremental share
FULL DISPATCH
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting2026-10-11 17:00 UTC
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 20262026-10-11 17:00 UTC
Humana surges after topping 2027 Medicare star ratings2026-10-09 18:15 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.